Marcelo C. Pasquini

2005–2025 年に発表

別表記
Marcelo C Pasquini
156
論文数
22,158
被引用数
72
h 指数
144
i10 指数

被引用数

Marcelo C. Pasquini の年別被引用数1990 年: 被引用 1 件1993 年: 被引用 1 件1999 年: 被引用 2 件2002 年: 被引用 1 件2003 年: 被引用 1 件2005 年: 被引用 2 件2007 年: 被引用 2 件2008 年: 被引用 1 件2009 年: 被引用 9 件2010 年: 被引用 23 件2011 年: 被引用 32 件2012 年: 被引用 76 件2013 年: 被引用 89 件2014 年: 被引用 90 件2015 年: 被引用 111 件2016 年: 被引用 80 件2017 年: 被引用 103 件2018 年: 被引用 96 件2019 年: 被引用 635 件2020 年: 被引用 982 件2021 年: 被引用 1,067 件2022 年: 被引用 817 件2023 年: 被引用 720 件2024 年: 被引用 1,337 件2025 年: 被引用 619 件2026 年: 被引用 20 件1991〜1992 年は被引用が無いため表示していません1994〜1998 年は被引用が無いため表示していません2000〜2001 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません2006 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,946 件、この内訳の 25.5%ドイツ: 引用元論文 844 件、この内訳の 7.3%イギリス: 引用元論文 684 件、この内訳の 5.9%イタリア: 引用元論文 659 件、この内訳の 5.7%フランス: 引用元論文 646 件、この内訳の 5.6%中国: 引用元論文 578 件、この内訳の 5%スペイン: 引用元論文 552 件、この内訳の 4.8%オランダ: 引用元論文 412 件、この内訳の 3.6%カナダ: 引用元論文 377 件、この内訳の 3.2%日本: 引用元論文 335 件、この内訳の 2.9%オーストラリア: 引用元論文 311 件、この内訳の 2.7%スイス: 引用元論文 298 件、この内訳の 2.6%
0%25.5%その他 25.2%

分野

  • Medicine90.8%
  • Immunology and Microbiology3.6%
  • Biochemistry, Genetics and Molecular Biology3.6%
  • Neuroscience0.9%
  • Engineering0.3%
  • Pharmacology, Toxicology and Pharmaceutics0.1%
  • その他0.7%

トピック

  • CAR-T cell therapy research13.3%
  • Hematopoietic Stem Cell Transplantation11%
  • Acute Myeloid Leukemia Research5.4%
  • Multiple Myeloma Research and Treatments4.9%
  • Acute Lymphoblastic Leukemia research4.2%
  • Immune Cell Function and Interaction3.6%
  • その他57.6%

共著者

全論文

検索で開く
  1. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    著者: , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2018 被引用: 3,445

  2. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

    著者: , , , , , , , , , , , , , , , , , - Nature Medicine 2024 被引用: 196

  3. Defining the Intensity of Conditioning Regimens: Working Definitions

    著者: , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2009 被引用: 1,797

  4. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam D. Cohen, Thomas H. Openshaw, Marcelo C. Pasquini, Sergio Giralt, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Amy Foley, Mariateresa Fulciniti, Kyle Hebert, Mehmet Samur, Kelly Masone, Michelle E. Maglio, Andrea A. Zeytoonjian, Omar Nadeem, Robert Schlossman, Jacob P. Laubach, Claudia E. Paba‐Prada, Irene M. Ghobrial, Aurore Perrot, Philippe Moreau, Hervé Avet‐Loiseau, Michel Attal, Kenneth C. Anderson, Nikhil C. Munshi - New England Journal of Medicine 2022 被引用: 463

  5. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

    著者: , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2022 被引用: 181

  6. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephan A. Grupp - Blood Advances 2020 被引用: 434

  7. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

    著者: , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2020 被引用: 711

  8. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 442

  9. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 被引用: 666

  10. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David A. Jacobsohn, Nahal Lalefar, Maxim Norkin, Nosha Farhadfar, Michael A. Pulsipher, Shalini Shenoy, Aleksandra Petrović, Kirk R. Schultz, Gregory A. Yanik, Edmund K. Waller, John E. Levine, James L.M. Ferrara, Bruce R. Blazar, Amelia Langston, John Horan, Leslie S. Kean - Journal of Clinical Oncology 2021 被引用: 249

  11. Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

    著者: , , , , , , - Biology of Blood and Marrow Transplantation 2009 被引用: 901

  12. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 168

  13. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Weisdorf, Juan Wu, Marcelo C. Pasquini, John Koreth - The Lancet Haematology 2019 被引用: 281

  14. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2021 被引用: 141

  15. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2023 被引用: 68

  16. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 被引用: 1,143

  17. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marlise R. Luskin, Rodrigo Martino, Richard T. Maziarz, Philip L. McCarthy, Taiga Nishihori, Rebecca L. Olin, Richard F. Olsson, Attaphol Pawarode, Edward Peres, Andrew R. Rezvani, David A. Rizzieri, Bipin N. Savani, Harry C. Schouten, Mitchell Sabloff, Matthew D. Seftel, Sachiko Seo, Mohamed L. Sorror, Jeff Szer, Baldeep Wirk, William A. Wood, Andrew Artz - Blood 2017 被引用: 296

  18. A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality

    著者: , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2015 被引用: 279

  19. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors.

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nina Worel, Mickey B C Koh, Mahmoud Aljurf, Hildegard Greinix, Yoshiko Atsuta, Wael Saber - Haematologica 2021 被引用: 237

  20. Decrease post-transplant relapse using donor-derived expanded NK-cells

    著者: , , , , , , , , , , , , , , , , , , , - Leukemia 2021 被引用: 104

  21. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

    著者: , , , , , , , , , , , , , , , , , , , - Blood 2021 被引用: 110

  22. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2017 被引用: 269

  23. Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eileen Tuschl, Rafeek A. Yusuf, Keming Zhan, Kathryn E. Flynn, Bronwen E. Shaw - Transplantation and Cellular Therapy 2024 被引用: 71

  24. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva - Leukemia 2020 被引用: 119